RecruitingPhase 1NCT07224490

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Sponsor

Stephanie B. Seminara, MD

Enrollment

40 participants

Start Date

Mar 10, 2026

Study Type

INTERVENTIONAL

Conditions

Long COVID SARS CoV-2 Neurodegeneration Reproductive Disorder

Summary

The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Kisspeptin 112-121 for people with long covid, neurodegeneration, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.